Description: A Rabbit Polyclonal antibody against CD80 from Human. This antibody is tested and validated for IHC, WB, ELISA

Description: A Rabbit Polyclonal antibody against CD80 from Human. This antibody is tested and validated for IHC, WB, ELISA

Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC-p:1:50-300, ELISA:1:10000-20000

Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100

Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB

Description: Rabbit polyclonal CD80 antibody

Description: Affinity purified Mouse polyclonal CD80 antibody

Description: Armenian Hamster monoclonal CD80 antibody

Description: Mouse monoclonal CD80 antibody

Description: Mouse monoclonal CD80 antibody

Description: Rat monoclonal CD80 antibody

Description: Mouse monoclonal CD80 antibody

Description: Rat monoclonal CD80 antibody

Description: Mouse monoclonal CD80 antibody

Description: Mouse monoclonal CD80 antibody

Description: Mouse monoclonal CD80 antibody

Description: Mouse monoclonal CD80 antibody

Description: Mouse monoclonal CD80 antibody

Description: Mouse monoclonal CD80 antibody

Description: Mouse monoclonal CD80 antibody

Description: Mouse monoclonal CD80 antibody

Description: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: Cluster of Differentiation 80 (also CD80 and B7-1) is a protein found on activated B cells and monocytes that provides a costimulatory signal necessary for T cell activation and survival. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. The CD80 genes encode B7-1 which are structurally similar members of the immunoglobulin superfamily expressed on a variety of hematopoietic cell types.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Description: A polyclonal antibody raised in Goat that recognizes and binds to Human CD80 (internal region). This antibody is tested and proven to work in the following applications:

Description: Rabbit Monoclonal CD80/B7 1 Antibody. Validated in IHC, WB and tested in Human.

Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human CD80 - C-terminal region. This antibody is tested and proven to work in the following applications:

Description: Antibody raised against CD80

Description: Armenian Hamster monoclonal CD80 antibody (FITC)

Description: Mouse monoclonal CD80 antibody (PE)

Description: Armenian Hamster monoclonal CD80 antibody (PE)

Description: Mouse monoclonal CD80 antibody (PE)

Description: Mouse monoclonal CD80 antibody (biotin)

Description: Armenian Hamster monoclonal CD80 antibody (biotin)

Description: Mouse monoclonal CD80 antibody (biotin)

Description: Armenian Hamster monoclonal CD80 antibody (allophycocyanin)

Description: Mouse monoclonal CD80 antibody (FITC)

Description: Rat monoclonal CD80 antibody (Allophycocyanin)

Description: Rat monoclonal CD80 antibody (biotin)

Description: Rat monoclonal CD80 antibody (FITC)

Description: Rat monoclonal CD80 antibody (PE)

Description: Antibody raised against CD80

Description: The CD80 antigen (B7, BB1) recognizes a 60 kDa transmembrane glycoprotein, member of the immunoglobulin family. This molecule shares with CD86 the capability to be the ligand for two structurally similar molecules expressed on T lymphocytes, CD28 and CD152 (CTLA-4). CD80 antigen is expressed on in vitro activated B lymphocytes. It is not expressed on the majority of resting B cells from peripheral blood but identifies a subpopulation of B cells that has been previously activated. The antigen is also expressed by HTLV-1 transformed T cells activated monocytes, and constitutively on dendritic cells. CD80 binding provides costimulatory signals for T cell activation.

Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).

Description: Rabbit polyclonal to CD80.

Description: Mouse monoclonal to CD80.

Description: (IN) CD80 peptide

Description: CD80 Peptide

Description: Mouse polyclonal to CD80

Description: Rabbit polyclonal to CD80

Description: Rabbit polyclonal to CD80

Description: Rat monoclonal CD80 antibody (Spectral Red)

Description: Rat monoclonal CD80 antibody (Azide Free)

Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.

Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.

Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.

Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.

Description: Recombinant Human T-lymphocyte activation antigen CD80(CD80),partial expressed in Mammalian cell

Description: Recombinant Human T-lymphocyte activation antigen CD80(CD80) expressed in in vitro E.coli expression system

Description: A Monoclonal antibody against Human CD80. The antibodies are raised in Mouse and are from clone 2A2. This antibody is applicable in IHC, ICC, E

Description: B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response.B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Description: B7­1 and B7­2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response.B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Description: B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response.B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Description: CD80 (B7-1) and CD86 (B7-2) together with their receptors CD28 and CTLA-4 constitute one of the dominant costimulatory pathways that regulate T cell and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon-gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. It has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites.

Description: CD80 (B7-1) and CD86 (B7-2) together with their receptors CD28 and CTLA-4 constitute one of the dominant costimulatory pathways that regulate T cell and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon-gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. It has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites.

Description: CD80 (B7-1) and CD86 (B7-2) together with their receptors CD28 and CTLA-4 constitute one of the dominant costimulatory pathways that regulate T cell and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells, and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon-gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. It has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites.

Description: Mouse Monoclonal to CD80

Description: Mouse monoclonal to CD80

Description: Mouse monoclonal to CD80

Description: Mouse monoclonal to CD80

Description: Mouse monoclonal to CD80

Description: Quantitative sandwich ELISA kit for measuring Mouse T-lymphocyte activation antigen CD80 (CD80) in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Description: Quantitative sandwich ELISA kit for measuring Mouse T-lymphocyte activation antigen CD80(CD80) in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 46.9pg/ml

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608), 1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),PerCP conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),RPE conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608),CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608), Concentration: 0.2mg/mL

Description: Primary antibody against CD80 (B7-1) (C80/1608), Concentration: 0.2mg/mL